Beta Bionics’ iLet bionic pancreas system significantly increased the percentage of time that adults with Type 1 diabetes spent with glucose levels between 70–180 mg/dl when compared to usual care therapy, according to a new study.

The study’s results also suggest that the iLet, using either the Senseonics (NYSE:SENS)Eversense continuous glucose monitoring system (CGM) or Dexcom (NSDQ:DXCM)G5 CGM for input, may provide safe and effective glycemic control for adults with T1D using insulin pumps or MDI therapy, Boston-based Beta Bionics said in a news release. The study’s results were announced at the ADA’s annual meeting in San Francisco.

Get the full story on our sister site, Drug Delivery Business.